What is Arch Therapeutics Debt-to-Equity?
Arch Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.90 Mil. Arch Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Arch Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-10.88 Mil.
Arch Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -0.63.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Arch Therapeutics's Debt-to-Equity or its related term are showing as below:
ARTH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.25 Med: -0.31 Max: 9.09
Current: -0.63
During the past 13 years, the highest Debt-to-Equity Ratio of Arch Therapeutics was 9.09. The lowest was -2.25. And the median was -0.31.
Arch Therapeutics Debt-to-Equity Historical Data
The historical data trend for Arch Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arch Therapeutics Debt-to-Equity Chart
|
Arch Therapeutics Annual Data
|
|
Trend |
Sep14 |
Sep15 |
Sep16 |
Sep17 |
Sep18 |
Sep19 |
Sep20 |
Sep21 |
Sep22 |
Sep23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
- |
-0.48 |
-1.56 |
-0.80 |
-0.75 |
|
Arch Therapeutics Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.31 |
-0.39 |
-0.75 |
-0.75 |
-0.63 |
Competitive Comparison of Arch Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Arch Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arch Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Arch Therapeutics's Debt-to-Equity falls into.
Arch Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Arch Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as
Arch Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arch Therapeutics (Arch Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
| Terrence W Norchi |
director, officer: President & CEO |
C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760 |
| Michael S Abrams |
officer: CFO and Treasurer |
64 RAMSHEAD ROAD, RAYNHAM MA 02767 |
| Laurence Hicks |
director |
C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702 |
| Guy L. Fish |
director |
C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702 |
| Dan Yrigoyen |
officer: Vice President, Sales |
C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702 |
| James R Sulat |
director |
|
| Punit Dhillon |
director |
5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| Richard E Davis |
officer: CFO & Treasurer |
|
| Avtar S Dhillon |
director |
C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
| Arthur L Rosenthal |
director |
100 CYBERONICS BLVD., HOUSTON TX 77058 |
| Alan Barber |
officer: Chief Financial Officer |
C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760 |
| William M Cotter |
officer: Chief Operating Officer |
C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616 |
Arch Therapeutics (Arch Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTH has been successfully added to your